http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-2601197-A1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_0597f9c318d2aeca86db94711c516383 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-436 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-437 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-537 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D498-20 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D498-22 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D491-20 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D491-22 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D498-20 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D498-22 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D491-22 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D491-20 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-437 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-436 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-537 |
| filingDate | 2011-08-04-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_7ae80a61156c11f0a7ee132889c4b0ec http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_08fc627da1f83a7e51194561b4240003 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_cb075355e768296aa84030f79a5875c8 |
| publicationDate | 2013-06-12-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | EP-2601197-A1 |
| titleOfInvention | Amino-iso-indole, amino-aza-iso-indole, amino-dihydroisoquinoline and amino-benzoxazine compounds as beta-secretase modulators and methods of use |
| abstract | The present invention comprises a new class of compounds useful for the modulation of Beta-secretase enzyme activity and for the treatment of Beta-secretase mediated diseases, including Alzheimer's disease (AD) and related conditions. In one embodiment, the compounds have a general Formula I: (I). In another embodiment, the compounds have a general Formula II: (II). In another embodiment, the compounds have a general Formula III: (III). Variables A 1 , A 2 , A 3 , A 4 , A 5 , A 6 , R 2 , R 7 , V, W, X, Y and Z of Formulas I, II and III are defined herein. The invention also includes use of these compounds in pharmaceutical compositions for treatment, prophylactic or therapeutic, of disorders and conditions related to the activity of beta-secretase protein. Such disorders include, for example, Alzheimer's Disease, cognitive deficits, cognitive impairment, schizophrenia and other central nervous system conditions related to and/or caused by the formation and/or deposition of plaque on the brain. The invention also comprises further embodiments of Formulas I, II and III, intermediates and processes useful for the preparation of compounds of Formulas I, II and III. |
| isCitedBy | http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2023057650-A1 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-4163922-A1 |
| priorityDate | 2010-08-05-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 933.